Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

(2012) Giancarlo Comi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity

(2012) Ulf Schulze-Topphoff et al.   PLoS One

Laquinimod, a once-daily oral drug in development for the treatment of relapsing–remitting multiple sclerosis

(2012) Wolfgang Brück et al.   Expert Review of Clinical Pharmacology

Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor

(2011) Jan Thöne et al.   AMERICAN JOURNAL OF PATHOLOGY

IκB kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-κB in the central nervous system

(2011) Jenni Raasch et al.   BRAIN

Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model

(2011) Hye Jung Kim et al.   FASEB JOURNAL

Insight into the mechanism of laquinimod action

(2011) W. Brück et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis

(2010) Christiane Wegner et al.   JOURNAL OF NEUROIMMUNOLOGY

Effects of Fumaric Acids on Cuprizone Induced Central Nervous System De- and Remyelination in the Mouse

(2010) Darius Moharregh-Khiabani et al.   PLoS One

Statin Therapy Inhibits Remyelination in the Central Nervous System

(2009) Veronique E. Miron et al.   AMERICAN JOURNAL OF PATHOLOGY

Oral laquinimod therapy in relapsing multiple sclerosis

(2009) Jana Preiningerova   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Transgenic Inhibition of Astroglial NF- B Improves Functional Outcome in Experimental Autoimmune Encephalomyelitis by Suppressing Chronic Central Nervous System Inflammation

(2009) R. Brambilla et al.   JOURNAL OF IMMUNOLOGY

Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate

(2009) V. Skihar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) G Comi et al.   LANCET

Distinct Stages of Myelination Regulated by γ-Secretase and Astrocytes in a Rapidly Myelinating CNS Coculture System

(2008) Trent A. Watkins et al.   NEURON